Aethlon Medical (NASDAQ:AEMD) Shares Cross Below 200-Day Moving Average of $1.18

Shares of Aethlon Medical, Inc. (NASDAQ:AEMDGet Rating) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.18 and traded as low as $0.73. Aethlon Medical shares last traded at $0.75, with a volume of 615,695 shares.

Analyst Upgrades and Downgrades

Separately, raised Aethlon Medical to a “sell” rating in a report on Tuesday, September 13th.

Aethlon Medical Price Performance

The stock has a market cap of $12.45 million, a price-to-earnings ratio of -1.02 and a beta of 0.75. The stock has a fifty day moving average of $1.15 and a 200 day moving average of $1.18.

Aethlon Medical (NASDAQ:AEMDGet Rating) last released its earnings results on Tuesday, June 28th. The medical equipment provider reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.13). Aethlon Medical had a negative return on equity of 59.57% and a negative net margin of 3,542.86%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $1.02 million. As a group, equities analysts expect that Aethlon Medical, Inc. will post 0.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Natixis purchased a new stake in Aethlon Medical, Inc. (NASDAQ:AEMDGet Rating) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,000 shares of the medical equipment provider’s stock, valued at approximately $28,000. Natixis owned 0.15% of Aethlon Medical at the end of the most recent quarter. 5.94% of the stock is owned by institutional investors and hedge funds.

About Aethlon Medical

(Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.

Featured Articles

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.